Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs PACB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRSP Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–2 Matrix Metrics)

CRSP Overall Winner 6-Pillar Tally: CRSP 3 – 2 PACB (1 Tie) Matrix Metrics: CRSP 8 – 2 PACB

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas PACB carries 38.0/100 (SELL) at $1.89 (N/M Forward P/E, -333.0% operating margin).

  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile PACB is in a Breakdown options structure phase (RSI 40.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs PACB
CRSP NASDAQ Head-to-Head Winner
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $48.88 · SMA50: $51.80
PACB NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.89
-3.83% 1D
Market Cap $615.1M
TTM Revenue $161M
Forward P/E N/M
Beta / 30D Vol 2.27β · 112% Vol
Unified Composite Score
38.0 / 100 SELL
Tech 15.0 Fund 35.0 Flow 57.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.8 · SMA20: $2.29 · SMA50: $2.02

6-Pillar Scorecard Institutional Category Breakdown (CRSP 3 – 2 PACB)

Columns: Metric · CRSP · PACB
1. Valuation Multiples CRSP
Forward P/E 23.4x N/M
Trailing P/E 23.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 7.8x
2. Growth & Scale CRSP
Revenue Growth (YoY) +1325.1% +5.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $25M $161M
Market Cap $4.1B $615.1M
3. Profitability & Quality PACB
Gross Margin N/A 27.7%
Operating Margin -2058.6% -333.0%
Net Profit Margin 0.0% -81.3%
Return on Equity (ROE) -25.6% -929.3%
4. Balance Sheet & Cash Flow PACB
Cash Generation (TTM) -$378M -$150M
Cash Flow Margin N/A -93.2%
Net Cash / Leverage $588M Net Debt (0.47x D/E) $649M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRSP
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 97.8% (52nd %ile) 92.6% (47th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.19x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (8) vs PACB (2)
Institutional Metric CRSP PACB Criterion Row Edge
Market Capitalization
Scale
$4.1B $615.1M Larger Scale CRSP
Trailing P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% +5.5% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% -333.0% Higher Margin PACB
Net Profit Margin
Profitability
0.0% -81.3% Higher Margin CRSP
Return on Equity (ROE)
Capital Efficiency
-25.6% -929.3% Higher ROE CRSP
52-Week Range Position
Momentum
1% ($40–$63) 34% ($1–$3) Stronger Trend PACB
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 2.27β · 112% Vol Lower Realized Risk CRSP
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 38.0 / 100 (SELL) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $161M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 27.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) -$150M ($649M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PACB +26.5 pp
CRSP: -17.54% · PACB: +8.96%
3M Horizon PACB +88.68 pp
CRSP: -23.33% · PACB: +65.35%
6M Horizon PACB +80.28 pp
CRSP: -16.37% · PACB: +63.91%
1Y Horizon PACB +36.18 pp
CRSP: -20.54% · PACB: +15.64%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue PACB Revenue CRSP Op. Margin PACB Op. Margin Margin Leader
FY2018 $0M $80M -5087.8% -128.4% PACB
FY2019 $290M $90M 16.1% -110.6% CRSP
FY2020 $0M $80M -49295.5% -132.3% PACB
FY2021 $910M $130M 40.8% -161.2% CRSP
FY2022 $0M $130M -56190.4% -239.4% PACB
FY2023 $370M $200M -60.0% -166.8% CRSP
FY2024 $40M $150M -1250.4% -308.0% PACB
FY2025 $0M $160M -18933.6% -346.2% PACB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PACB BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 92.6%
IV Percentile 47th %ile
Put/Call OI Skew 0.19x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact PACB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PACB Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $615.1M market capitalization and -333.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs PACB Key Questions & Quantitative Answers

As of Nov 16, 2026, CRISPR Therapeutics AG (CRSP) is the stronger overall head-to-head candidate over Pacific Biosciences of California, Inc. (PACB) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). CRSP carries a Unified Composite Score of 48.6/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas PACB carries 38.0/100 (SELL) at $1.89 (N/M Forward P/E, -333.0% operating margin). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile PACB is in a Breakdown options structure phase (RSI 40.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRSP leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with PACB at +5.5% YoY revenue growth and +0.0% YoY earnings growth on $161M TTM revenue (27.7% gross margin, -333.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while PACB shifted +100.0%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PACB.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PACB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (-93.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus PACB (-929.3% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, PACB carries 92.6% implied volatility (47th %ile, Balanced (25th–60th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.27β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.